News

DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange
DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
DiaMedica Announces Pricing of Initial Public Offering and Nasdaq Listing
DiaMedica Therapeutics Has Applied to List its Common Shares on Nasdaq, Announces Share Consolidation
DiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders
DiaMedica Therapeutics and Ahon Pharma, a Fosun Pharma Portfolio Company, Announces Signing of License Agreement for DM199 in China for Acute Ischemic Stroke
DiaMedica Therapeutics Announces the Appointment of Dr. Harry Alcorn Jr. as Chief Medical Officer
DiaMedica Announces Positive Results From FDA Meeting on Planned Clinical Trial in Patients with Chronic Kidney Disease
DiaMedica Therapeutics Announces Appointment of Scott Kellen as Chief Financial Officer
DiaMedica to Present at the MicroCap Conference on April 10th in New York City at the Essex House